MUC5AC and ganglioneuroma: Although topical ocular application of drug using biodegradable in situ gelling carriers has been shown to achieve longer therapeutic action, the EGCG-containing GN cannot completely relieve dry eye symptoms, as indicated by a relatively high rose bengal staining score and comparable goblet cell number and ocular surface mucin expression to those of rabbits immediately following BAC treatment.